Artemisinin and derivatives
Artemisinin and its derivatives are drugs used to fight malaria infection [Articles:
19851082,
19926036]. Recombinant CYP2A6 metabolizes artemisinin and CYP2A6 inhibition attenuates the rate of drug disappearance in human microsomes
in vitro [Article:
10583023]
. However, CYP2B6 and CYP3A4 enzymes are thought to have a greater role in artemisinin metabolism [Article:
10583023] (see the
PharmGKB Artemisinin and Derivatives Pathway, Pharmacokinetics). Artemisinin derivatives (arteether, artemether, artesunate) were developed to enhance drug bioavailability, and are used in combination with a second unrelated slower acting drug, in order to initially rapidly eradicate malaria parasites within red blood cells, and then kill any residual parasites [Articles:
19851082,
19926036]. CYP2A6 is the major CYP450 enzyme involved in artesunate metabolism, forming dihydro-artemisinin, which is then inactivated by UGT enzymes (see the
PharmGKB Artemisinin and Derivatives Pathway, Pharmacokinetics) [Articles:
12920490,
19926036]. Therefore,
CYP2A6 alleles which confer loss-of-function or decreased function may affect metabolism of these anti-malarial drugs. However, studies investigating urinary metabolites after dosing with artemisinin or derivatives, and use concurrent coumarin or nicotine probe drugs, see no clear correlation between
CYP2A6 genotype and an effect on PK or enzyme activity [Articles:
18064444,
18979093]. Artemisinin and derivatives induce
CYP2B6 expression [Article:
18350255; 12844133], further complicating
CYP2A6 association studies. Studies controlling for CYP2B6 status and with larger numbers are therefore required to investigate the clinical implications of
CYP2A6 genotype on the metabolism of artemisinin and its derivatives.